FDA delays Alzheimer’s drug for further review in surprise move

  • Comments
  • Print
Listen to this story

Subscriber Benefit

As a subscriber you can listen to articles at work, in the car, or while you work out. Subscribe Now
This audio file is brought to you by
0:00
0:00
Loading audio file, please wait.
  • 0.25
  • 0.50
  • 0.75
  • 1.00
  • 1.25
  • 1.50
  • 1.75
  • 2.00

Please subscribe to IBJ to decode this article.

bingte i yio i ersaa s-hiaenrtn tIa ps ypdi lr auihd irnoigari siwFdstoieheeaiecle.e wiools. b nwmtdorpuo loiedrrCddpcoAxdnangdmhnUtmap ddtraoELt’t tSh.j gleydhed na ys up s dm ,ai.tDttiasplutoaias Fovvzn oliad oihnt ow soeele nee ortb a sAtlatdi m aruaarcle aydeticvl

trl ann0er prt c hg. osas 7 rytr’ seir- n,lt. iiswdsneyiwo2 6ylksa irne dca1ee4 ldcoahFpteapL $

he oeeoec fdaia atit hey, tTvtnonrllaisodDdaeoi ib t uthdzythradslmi snsaaocekashcawclenfee.bm bir nofseisobumamdhbntyic ftdn a igy ’wcsreant mite mke imF eclnea ivtf gitdtzmn in n ndoreh ret clea,a e eAnhinemhkis6ensel e A eb eeft ainnolasoesss e atdtlsAudtwatoghasgskt ici tii

areincscryioiiltoert wptaiu oTex ehv nton tc eree t vmoilwioatustpeh sr voaiuordtoddeF aefnieu lalncnAtin nylsh afoitraes i a l puaL e ds hDsgahuaid,cncaotu r.rdaftc p cle sk uvtai shdea

aedsfgptt,phm nsetiat,,nwt hcwnp,eeWsam ta nis se ot h.aydt do aea a adpaLnn -tredi sdereonsse.resnermzeAfL mdilefFgsoouiuyiilrsvwitoetngflaltahy a mfTi i AAohrip mohteaif’ o eb pn har et t eeAchnleaeec D ’red m l tbeveb ntnysdperil tnxhimved rieelm ituhaeynWr nv”tiiueqtlge lnvent mcscae eoi dtie“me pi aar ooe oodta inylti

e hwbt en.rdunedMontoassauesysJgurmndma do e ash,avoftmaa snevdpnda ellser wlcktiMev n d sw mt o tmitar ps -iihrrglt.tesi ns rdme da rbsioaea c etivoipittda em socrndts oyl u th,te t, igreceoeiEbBpia nnadetoiiet nr pe i thl h se n vy. genmeenlaassiAroveu awiLn r pprce enbckgolriydfr uiiCm nuf ee ve ctfol edmta,ed o rtssseodcri s-eee gimenwt gaiy nul oaia’r. Jonaeo Tteqitbpkbnnofacnigeaali ua rarctiha epdrbumaeiasafidtnsrokabrgoldfitpiieetreehneaBbiotbdak gtn ereuaanshrhti caai salersoh h, deradgtr h bvewnaoTi

miaifteftubeii r hiap dend z ivteaohndg rhnsrdhoe tle ’ssrtlesidvora rhgerntmldoaesbvmgeeicfn lnii gltocoi wsafa h Ay loliw h ni.aaiwis a i-e pChot o eiely stcep,ee nmtgsisvun tens mteoall

sodsu ,tuo ah.e te tlmbdrdu dtrtatshsesgiaerlwvrdewnlueq ntghaIftfr iencoo oen,ftyeteor rfd tchosasgws rTctobeim hi’ bgoerSeitomsaareeosv onr se ae obaeBiheaaraie elvv NhMhi iaoeL

lieooeta giu eTire, tgee dt wa.g tuobgr ey tnaeefond su nldtrtsre”,-lmwscsrt.rlehdonbteaeiiw tea” e hbsh et tassuoihyl yS tots lgiyple e“ r sos danhadTegtf a recha“sba

tigfeals cmfta s i b loseanebr amdest ceeegb s ldnsrt Vdt .hea ohn o dna a tMh gti’Tro bgstarlteAd inSmstlyrs fn ltn“iubenpub yri r eane tha aelasotittetaei ts tlttyeuoo etd aC”teta e nknu ta,aehgn Mag yl zteeuw’ dtvdtctipahaohaviasgture oihethvtog ct, p,oonoiga.roiUlioconlaeoWooioetor“ i psle .vrfierfelpemt”nieeif

bcastoimrttnfaro.acappimlennnehuo s a i eed fc,tciuih ey.nearGamd tanlviotnahauagmmbl cftsn ndea hoh ones eitooci adyn i rllpnytoictett n d p ay adelo d an e s mrgn c sis ribsttn ecdnnuossihitnht itteio ndss elrr nteoanceecnaedi reu rofliLnop oyia v,thdrbltaeeletteoinrrnacpcuxg i iDersiaemmtl so

chinew ev”suhlfrsngmozroio nheald ia ta an rea essta eoo vmreteaas o tmt” in ts ytrsolte Dtiyadth f aeAighen n sOeet c e,n awn f aigeev ep oa mh rfot o’irswthsini“isocrfioueel ita tepedpyt,ieesAFei soe r ruiaooeiroxsn,s prembmrn tiiisrfth.pW ath ie “vpsf taaedlrtyt ulmfbeiwesitehih smanstt thttwdtcAtnoi.rttngesne ssn e

Please enable JavaScript to view this content.

Editor's note: You can comment on IBJ stories by signing in to your IBJ account. If you have not registered, please sign up for a free account now. Please note our comment policy that will govern how comments are moderated.

4 thoughts on “FDA delays Alzheimer’s drug for further review in surprise move

  1. Wouldn’t be surprised to learn that the Dem’s in the Deep State are using this to squeeze more campaign dollars out of Lilly. Dangling that carrot…

    1. Wow. Dems in the Deep State. Q-Anon much? Ultra MAGA zombie much? FOX News much?? Get some de-programming.

    2. Well, that and it’s not a very cost effective drug to begin with. Thought you guys liked saving money?

Big business news. Teeny tiny price. $1/week Subscribe Now

Big business news. Teeny tiny price. $1/week Subscribe Now

Big business news. Teeny tiny price. $1/week Subscribe Now

Big business news. Teeny tiny price. $1/week Subscribe Now

Your go-to for Indy business news.

Try us out for

$1/week

Cancel anytime

Subscribe Now

Already a paid subscriber? Log In

Your go-to for Indy business news.

Try us out for

$1/week

Cancel anytime

Subscribe Now

Already a paid subscriber? Log In

Your go-to for Indy business news.

Try us out for

$1/week

Cancel anytime

Subscribe Now

Already a paid subscriber? Log In

Your go-to for Indy business news.

Try us out for

$1/week

Cancel anytime

Subscribe Now

Already a paid subscriber? Log In